

0904254-3

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/38, 31/41, 31/435, 31/505, C07D 239/02, 271/06, 285/12, 333/38, 213/28		A1	(11) International Publication Number: WO 96/19988
			(43) International Publication Date: 4 July 1996 (04.07.96)
(21) International Application Number: PCT/US95/16711		(74) Agents: KANAGY, James, M. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).	
(22) International Filing Date: 21 December 1995 (21.12.95)			
(30) Priority Data: 08/363,506 23 December 1994 (23.12.94) US		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
(60) Parent Application or Grant (63) Related by Continuation US 08/363,506 (CON) Filed on 23 December 1994 (23.12.94)			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): CHRISTENSEN, Siegfried, B., IV [US/US]; 2216 Race Street, Philadelphia, PA 19103 (US). KARPINSKI, Joseph, M. [US/US]; 308 North Charlotte Street, Pottstown, PA 19464 (US). RYAN, M., Dominic [CA/US]; 2146 Foxtail Drive, Pottstown, PA 19464 (US). BENDER, Paul, E. [US/US]; 504 Lilac Lane, Cherry Hill, NJ 08003 (US).			
(54) Title: 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS			
(57) Abstract			
The present invention relates to novel 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).			